PGPallavi Galera

Pallavi Galera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pallavi Galera has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmet Dogan

    Memorial Sloan Kettering Cancer Center, New York, NY

    3 shared publications
  • Ahmet Dogan

    Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

    2 shared publications
  • Anita Kumar

    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA

    2 shared publications
  • Shenon Sethi

    Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA

    2 shared publications
  • Alexander Chan

    Memorial Sloan Kettering Cancer Center

    1 shared publication
  • Andriy Derkach

    Department of Epidemiology and Biostatistics

    1 shared publication

Latest Publications

  • Pathology, Clinical Features, and Natural History of Low-Grade B-Cell Lymphomas With Primary Osseous Presentation

    by Shenon Sethi, Irem Isgor, Pallavi K. Galera, Efrat Luttwak, Heiko Schöder, Gilles A. Salles, Ahmet Dogan

    Primary bone lymphomas are rare, and most reported cases represent diffuse large B-cell lymphoma. Low-grade B-cell lymphomas presenting with primary osseous involvement (PB-LGBCLs) are far less common, and their clinicopathologic features and clinical course remain poorly defined. We retrospectively analyzed 32 PB-LGBCLs diagnosed at a single tertiary cancer center. Cases were included when the disease presented with bone-only involvement, with or without contiguous soft tissue extension, and without lymph node, spleen, or noncontiguous extranodal disease at initial diagnosis. Staging marrow and low-level peripheral blood involvement were recorded but were not used as exclusion criteria. The cohort included follicular lymphoma (FL; 22/32, 69%), marginal zone lymphoma (MZL; 6/32, 19%), lymphoplasmacytic lymphoma (LPL; 2/32, 6%), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; 2/32, 6%). Median age was 64 years (range: 39 to 87), and 25/32 patients (78%) had multifocal skeletal disease, most often involving the pelvis and spine. Primary bone FL frequently showed features typical of conventional FL, including germinal center B-cell phenotype, frequent BCL2 rearrangement, and recurrent FL-associated mutations. Non-FL subtypes showed clinicopathologic features and molecular findings compatible with their systemic counterparts. Among 27 patients with more than 6 months of follow-up, disease progression or transformation occurred in 12 patients. Three FLs transformed to diffuse large B-cell lymphoma. No deaths occurred. PB-LGBCLs are rare with FL as the most common subtype and show heterogeneous biology and clinical behavior. Recognition of this presentation is important to avoid misclassification as aggressive lymphoma, nonhematolymphoid bone neoplasm, or reactive condition.

  • Immunophenotyping of Acute Myeloid Leukemia

    by Pallavi Kanwar Galera, Raul Braylan

  • Correlation between TP53 mutational status and digital quantification of p53 immunohistochemistry in mantle cell lymphoma

    by Mingfei Yan, Shenon Sethi, Zachary Epstein-Peterson, Anita Kumar, Ahmet Dogan, Pallavi Galera

    TP53 mutation is a significant negative prognostic factor in mantle cell lymphoma (MCL). While p53 immunohistochemical (IHC) staining is frequently used to evaluate TP53 mutation status, specific cut-offs correlating with mutations remain undefined and largely empirical. This study analyzed tumor specimens from 172 patients with MCL with both p53 IHC and TP53 mutation data, categorizing p53 nuclear expression into four groups (0 + , 1 + , 2 + , and 3 +) using digital image analysis. We established IHC cut-offs with 100% specificity for identifying TP53 non-truncating mutations: 5% for 3 + nuclei, 50% for combined 2 + and 3 + nuclei, and an H-score of 150. The combined 2 + and 3 + nuclei percentage showed the highest sensitivity and negative predictive value. Notably, p53 IHC expression did not significantly correlate with the variant allele frequencies (VAFs) of TP53 missense mutations. However, patients with both TP53 missense and ATM mutations displayed lower p53 expression compared to those with only TP53 missense mutations. TP53 truncating mutations affecting the DNA-binding domain were associated with null p53 staining, while truncating mutations in the tetramerization domain showed weak to moderate staining. Cases with single nucleotide substitutions involving TP53 splice sites showed weak to moderate p53 staining and lacked 3 + nuclei. In cases where multiple types of TP53 mutations coexisted, the clonally dominant mutation influenced the overall p53 expression level. Finally, we observed significantly worse overall survival in patients demonstrating p53 overexpression by using the above mentioned IHC cut-offs. This study provides essential evidence for interpreting p53 IHC staining and may potentially guide rapid risk stratification of patients with MCL, especially in limited resource settings.


  • Open Access

    Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment

    by Sary El Daker, David Qualls, Andriy Derkach, Samida Beqaj, Leonardo Boiocchi, Venkatraman Seshan, Jeeyeon Baik, Menglei Zhu, Gilles Salles, Ahmet Dogan, et al.

    Follicular lymphoma (FL) is an indolent B-cell lymphoma with a heterogenous disease course, and patients may not require immediate treatment upon diagnosis. Scrutiny of its microenvironment may provide key insights into lymphomagenesis and enhancement of therapeutic options. We analyzed the T-cell composition of a large, well-annotated follicular hyperplasia (FH; N=43) cohort utilizing standardized high dimensionality flow cytometry (>150,000 cells analyzed/sample) and a novel reproducible analytical pipeline leading to identification of even minor T-cell subsets. This baseline reference set was compared to prospectively collected FL samples (N=91) from untreated patients (FL-UT) and patients with relapsed/refractory disease (FL-RR). Compared to FH, both FL-UT and FL-RR specimens exhibited depletion of CD4+ and CD8+ naïve subsets and were characterized by an immune suppressive microenvironment enriched in specific inhibitory T cells, along with exhausted memory T cells overexpressing varying combinations of immune checkpoint receptors. FL specimens showed enrichment of T-follicular regulatory cells (TFR) and two highly suppressive regulatory T-cell (T-reg) populations expressing TIGIT and CTLA4 (TC) and PD1, TIGIT, CTLA4, and TIM3 (PTCTi). FL-UT cases with either increased T-reg TC or increased T-follicular helper cells (TFH) showed reduced time to first treatment (</= 3 months). Our study suggests that changes in the balance between TFR, T-reg and TFH may lead to greater tumor growth and identifies factors that are associated with earlier time to treatment in FL-UT. We also identified specific combinations of immune checkpoint receptors that may be used to target specific inhibitory T-cell subsets and regulatory cells in FL to increase anti-tumor immune response.


  • Open Access

    Acute myeloid leukemia with mixed phenotype is characterized by RUNX1 mutations, stemness features and limited lineage plasticity

    by Pallavi Galera, Deepika Dilip, Andriy Derkach, Alexander Chan, Yanming Zhang, Sonali Persuad, Tanmay Mishera, Ying Liu, Christopher Famulare, Qi Gao, et al.

    Mixed phenotype (MP) in acute leukemias poses unique classification and management dilemmas and can be seen in entities other than de novo mixed phenotype acute leukemia (MPAL). Although WHO classification empirically recommends excluding AML with myelodysplasia related changes (AML-MRC) and therapy related AML (t-AML) with mixed phenotype (referred to as “AML-MP”) from MPAL, there is lack of studies investigating the clinical, genetic, and biologic features of AML-MP. We report the first cohort of AML-MP integrating their clinical, immunophenotypic, genomic and transcriptomic features with comparison to MPAL and AML without MP. Patients with AML-MP share similar clinical and genetic features to its AML counterpart but differs from MPAL. AML-MP harbors more frequent RUNX1 mutations than AML without MP and MPAL. RUNX1 mutations or complex karyotypes did not impact the survival of MPAL patients. Unsupervised hierarchal clustering based on immunophenotype identified biologically distinct clusters with phenotype/genotype correlation and outcome differences. Furthermore, transcriptomic analysis showed an enrichment for stemness signature in AML-MP and AML without MP as compared to MPAL. Lastly, MPAL but not AML-MP often switched to lymphoid only immunophenotype after treatment. Expression of transcription factors critical for lymphoid differentiation were upregulated only in MPAL, but not in AML-MP. Our study for the first time demonstrates that AML- MP clinically and biologically resembles its AML counterpart without MP and differs from MPAL, supporting the recommendation to exclude these patients from the diagnosis of MPAL. Future studies are needed to elucidate the molecular mechanism of mixed phenotype in AML. Key points: AML-MP clinically and biologically differs from MPAL but resembles AML. AML-MP shows RUNX1 mutations, stemness and limited lineage plasticity.


  • Open Access

    The Functional Immunophenotypic Profile of Kikuchi Fujimoto Disease: Comparison with Systemic Lupus Erythematosus

    by Pallavi Galera, Julie Alejo, Racquel Valadez, Theresa Davies-Hill, Madhu P. Menon, Sarfaraz Hasni, Elaine S. Jaffe, Stefania Pittaluga

    Kikuchi Fujimoto Disease (KFD) is a rare form of localized lymphadenopathy, commonly affecting young Asian females with a self-limited course. The immunopathogenic mechanisms underlying KFD are still not well understood. KFD and systemic lupus erythematosus (SLE) share several histologic and clinical features, thus posing a diagnostic challenge. The aim of this study was to elucidate the in-situ distribution of immune cells and the cytokine/chemokine milieu of KFD utilizing immunohistochemistry to identify key cellular elements and RNAscope to assess cytokine and chemokine production. This study further compared the clinical, morphologic, and immunologic features of KFD to SLE.18 KFD, 16 SLE and 3 reactive lymph nodes were included. In contrast to KFD and reactive lymph nodes, SLE patients frequently exhibited generalized lymphadenopathy and had significantly higher frequency of systemic manifestations. Both KFD and SLE lymph nodes revealed overlapping morphologic findings with few distinguishing features namely the presence of capsular fibrosis and plasmacytosis in SLE and predominance of CD8-positive T cells in KFD.RNAscope studies in the KFD cohort revealed significantly higher amounts of interferon γ (IFN-γ), CXCL9 and CXCL10 in comparison to the SLE and reactive lymph nodes. These findings suggest a T-helper cell 1 (Th1) response, driven by IFN-γ and IFN-γ induced CXCL9 and CXCL10, is pivotal in the pathogenesis of KFD and is less evident in lymph nodes from SLE patients. Distinguishing histological features between KFD and SLE are subtle. Studying the cytokine/chemokine environment provides valuable insight into the pathophysiology of KFD. In addition, assessing the production of these cytokines/chemokines may provide further diagnostic help in differentiating KFD from SLE.